A Nationwide Phase 2 Trial of Patients With Smoldering and Active Multiple Myeloma (MM)
A Nationwide Phase 2 Trial of Patients With Smoldering and Active Multiple Myeloma (MM)
Enrolling by invitation · NCT03815279 · Registry updated 2019-08-16Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Nationwide Phase 2 Trial of Patients With Smoldering and Active Multiple Myeloma (MM) | Blood Protein Disorders, Hemic and Lymphatic Diseases, Hypergammaglobulinemia, Neoplasms by Histologic Type, cardiovascular disorder, hematologic disorder, hemorrhagic disease, immune system disorder, immunoproliferative disorder, lymphoproliferative syndrome, monoclonal gammopathy, neoplasm, plasma cell neoplasm, precancerous condition, smoldering plasma cell myeloma, vascular disorder, vascular hemostatic disease | Enrolling by invitation | Phase 2 | 2019-08-16 | NCT03815279 |
5 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Amgen | 180 |
| Celgene | 53 |
| Landspitali University Hospital | 19 |
| Memorial Sloan Kettering Cancer Center | 753 |
| University of Iceland | 17 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Landspitali University Hospital | Reykjavik | Iceland | 8 |